Four out of 57 tested patients (7%) had a T315I mutation at the time of CML-MBP diagnosis (Table 1), and 1/8 patients treated with ponatinib had a detectable T315I mutation. The gene discussed is MBP; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.